ADI 100
Alternative Names: ADI™-100Latest Information Update: 28 Aug 2026
At a glance
- Originator ADiTxT Therapeutics
- Developer Adimune; ADiTxT Therapeutics
- Class Antihyperglycaemics; Antipsoriatics; Antispastics; DNA; Gene therapies
- Mechanism of Action Apoptosis stimulants; Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Stiff-person syndrome; Type 1 diabetes mellitus
- No development reported Psoriasis
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Psoriasis in USA (Intradermal)
- 25 Aug 2025 Adimune plans to seek FDA submission and approval for first-in-human trials in early 2026
- 15 Apr 2025 Preclinical trials in Stiff-person syndrome in USA (unspecified route), prior to April 2025